SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-20-009653
Filing Date
2020-08-06
Accepted
2020-08-06 16:11:55
Documents
66
Period of Report
2020-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q nbrv-20200630x10q.htm   iXBRL 10-Q 2124024
2 EX-10.2 nbrv-20200630xex10d2.htm EX-10.2 483591
3 EX-31.1 nbrv-20200630xex31d1.htm EX-31.1 10534
4 EX-31.2 nbrv-20200630xex31d2.htm EX-31.2 10564
5 EX-32.1 nbrv-20200630xex32d1.htm EX-32.1 5730
6 EX-32.2 nbrv-20200630xex32d2.htm EX-32.2 5578
  Complete submission text file 0001558370-20-009653.txt   8248550

Data Files

Seq Description Document Type Size
7 EX-101.SCH nbrv-20200630.xsd EX-101.SCH 55691
8 EX-101.CAL nbrv-20200630_cal.xml EX-101.CAL 52521
9 EX-101.DEF nbrv-20200630_def.xml EX-101.DEF 248187
10 EX-101.LAB nbrv-20200630_lab.xml EX-101.LAB 504020
11 EX-101.PRE nbrv-20200630_pre.xml EX-101.PRE 415508
12 EXTRACTED XBRL INSTANCE DOCUMENT nbrv-20200630x10q_htm.xml XML 1211421
Mailing Address 1000 CONTINENTAL DRIVE SUITE 600 KING OF PRUSSIA PA 19406
Business Address 56 FITZWILLIAM SQUARE DUBLIN L2 2 (610) 816-6640
Nabriva Therapeutics plc (Filer) CIK: 0001641640 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37558 | Film No.: 201081733
SIC: 2834 Pharmaceutical Preparations